Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Urogen Pharma (URGN) reported a Q4 loss of $0.80 per share, missing the Zacks Consensus Estimate of a $0.74 loss. This is a larger loss compared to $0.72 per share a year ago.
March 10, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Urogen Pharma reported a Q4 loss of $0.80 per share, missing the expected loss of $0.74 and showing a larger loss than the previous year.
The reported loss per share of $0.80 is worse than both the consensus estimate and the previous year's loss, indicating potential negative sentiment and pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100